Cargando…
Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion
Platelet concentrate (PC) transfusion seeks to provide haemostasis in patients presenting severe central thrombocytopenia or severe bleeding. PCs may induce adverse reactions (AR) that can occasionally be severe (SAR). PCs contain active biomolecules such as cytokines and lipid mediators. The proces...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149858/ https://www.ncbi.nlm.nih.gov/pubmed/37138863 http://dx.doi.org/10.3389/fimmu.2023.1031968 |
_version_ | 1785035237188698112 |
---|---|
author | Duchez, Anne-Claire Fauteux-Daniel, Sébastien Sut, Caroline Ebermeyer, Theo Heestermans, Marco Arthaud, Charles-Antoine Eyraud, Marie-Ange Prier, Amélie Audoux, Estelle Bertrand-Michel, Justine Payrastre, Bernard Garraud, Olivier Boilard, Eric Hamzeh-Cognasse, Hind Cognasse, Fabrice |
author_facet | Duchez, Anne-Claire Fauteux-Daniel, Sébastien Sut, Caroline Ebermeyer, Theo Heestermans, Marco Arthaud, Charles-Antoine Eyraud, Marie-Ange Prier, Amélie Audoux, Estelle Bertrand-Michel, Justine Payrastre, Bernard Garraud, Olivier Boilard, Eric Hamzeh-Cognasse, Hind Cognasse, Fabrice |
author_sort | Duchez, Anne-Claire |
collection | PubMed |
description | Platelet concentrate (PC) transfusion seeks to provide haemostasis in patients presenting severe central thrombocytopenia or severe bleeding. PCs may induce adverse reactions (AR) that can occasionally be severe (SAR). PCs contain active biomolecules such as cytokines and lipid mediators. The processing and storage of PCs creates so-called structural and biochemical storage lesions that accumulate when blood products reach their shelf life. We sought to investigate lipid mediators as bioactive molecules of interest during storage and review associations with adverse reactions post-transfusion. To facilitate understanding, we focused on single donor apheresis (SDA) PCs with approximately 31.8% of PCs being delivered in our setting. Indeed, pooled PCs are the most widely transfused products, but the study of a single donor lipid mediator is easier to interpret. We are investigating key lipid mediators involved in AR. Adverse reactions were closely monitored in accordance with current national and regional haemovigilance protocols. Residual PCs were analysed post-transfusion in a series of observations, both with and without severe reactions in recipients. A decrease in the lysophosphatidylcholine species to produce the lysophosphatidic acid species has been observed during storage and in the case of AR. Lysophosphatidic acid increased with primarily platelet-inhibitor lipids. Anti-inflammatory platelet-induced inhibition lipids were weakly expressed in cases of severe adverse reactions. We therefore propose that a decrease in lysophosphatidylcholine and an increase in lysophosphatidic acid can prospectively predict serious adverse transfusion reactions. |
format | Online Article Text |
id | pubmed-10149858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101498582023-05-02 Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion Duchez, Anne-Claire Fauteux-Daniel, Sébastien Sut, Caroline Ebermeyer, Theo Heestermans, Marco Arthaud, Charles-Antoine Eyraud, Marie-Ange Prier, Amélie Audoux, Estelle Bertrand-Michel, Justine Payrastre, Bernard Garraud, Olivier Boilard, Eric Hamzeh-Cognasse, Hind Cognasse, Fabrice Front Immunol Immunology Platelet concentrate (PC) transfusion seeks to provide haemostasis in patients presenting severe central thrombocytopenia or severe bleeding. PCs may induce adverse reactions (AR) that can occasionally be severe (SAR). PCs contain active biomolecules such as cytokines and lipid mediators. The processing and storage of PCs creates so-called structural and biochemical storage lesions that accumulate when blood products reach their shelf life. We sought to investigate lipid mediators as bioactive molecules of interest during storage and review associations with adverse reactions post-transfusion. To facilitate understanding, we focused on single donor apheresis (SDA) PCs with approximately 31.8% of PCs being delivered in our setting. Indeed, pooled PCs are the most widely transfused products, but the study of a single donor lipid mediator is easier to interpret. We are investigating key lipid mediators involved in AR. Adverse reactions were closely monitored in accordance with current national and regional haemovigilance protocols. Residual PCs were analysed post-transfusion in a series of observations, both with and without severe reactions in recipients. A decrease in the lysophosphatidylcholine species to produce the lysophosphatidic acid species has been observed during storage and in the case of AR. Lysophosphatidic acid increased with primarily platelet-inhibitor lipids. Anti-inflammatory platelet-induced inhibition lipids were weakly expressed in cases of severe adverse reactions. We therefore propose that a decrease in lysophosphatidylcholine and an increase in lysophosphatidic acid can prospectively predict serious adverse transfusion reactions. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10149858/ /pubmed/37138863 http://dx.doi.org/10.3389/fimmu.2023.1031968 Text en Copyright © 2023 Duchez, Fauteux-Daniel, Sut, Ebermeyer, Heestermans, Arthaud, Eyraud, Prier, Audoux, Bertrand-Michel, Payrastre, Garraud, Boilard, Hamzeh-Cognasse and Cognasse https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Duchez, Anne-Claire Fauteux-Daniel, Sébastien Sut, Caroline Ebermeyer, Theo Heestermans, Marco Arthaud, Charles-Antoine Eyraud, Marie-Ange Prier, Amélie Audoux, Estelle Bertrand-Michel, Justine Payrastre, Bernard Garraud, Olivier Boilard, Eric Hamzeh-Cognasse, Hind Cognasse, Fabrice Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion |
title | Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion |
title_full | Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion |
title_fullStr | Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion |
title_full_unstemmed | Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion |
title_short | Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion |
title_sort | bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149858/ https://www.ncbi.nlm.nih.gov/pubmed/37138863 http://dx.doi.org/10.3389/fimmu.2023.1031968 |
work_keys_str_mv | AT duchezanneclaire bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT fauteuxdanielsebastien bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT sutcaroline bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT ebermeyertheo bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT heestermansmarco bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT arthaudcharlesantoine bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT eyraudmarieange bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT prieramelie bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT audouxestelle bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT bertrandmicheljustine bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT payrastrebernard bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT garraudolivier bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT boilarderic bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT hamzehcognassehind bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion AT cognassefabrice bioactivelipidsasbiomarkersofadversereactionsassociatedwithapheresisplateletconcentratetransfusion |